4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Aging is a gradual and irreversible pathophysiological process. It presents with declines in
tissue and cell functions and significant increases in the risks of various aging-related …

Background In patients with ST-segment elevation myocardial infarction (STEMI) with
multivessel coronary artery disease, the time at which complete revascularization of …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

These guidelines will be updated every four years. Vascular centres are encouraged to audit
implementations made as a result of the guidelines. Audit cycles should be repeated and …

Chronic kidney disease (CKD) is defined by a low glomerular filtration rate or high
albuminuria, and affects 15–20% of adults globally. CKD increases the risk of various …